Sana Biotechnology：建立在临床前第一阶段基础上的 10 亿美元市值 (SANA)
· seekingalpha.com
Sana Biotechnology 的核心资产仍为 SC291，该资产已被重新调整用途，用于治疗严重自身免疫性疾病，而非血液肿瘤。了解为何 SANA 股票被评为买入。
Sana Biotechnology, Inc. ( SANA ) has recently undergone a big pipeline reset . Up to 2024, they mainly focused on oncology, specifically blood cancers, but aft...